Brandon Scalea

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung cancer.

Funda Meric-Bernstam, MD, discusses the potential for the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in the treatment of metastatic renal cell carcinoma.

Evan Y. Yu, MD, discusses updated data from cohort A of the KEYNOTE-365 trial in patients with metastatic castration-resistant prostate cancer.

Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.

Ezzat Elhassadi, MD, highlights research being done to address the unmet need of patients with p53-mutant mantle cell lymphoma and the challenges faced in the current treatment paradigm.

Anthony B. El-Khoueiry, MD, provides insight on the rapidly evolving treatment options in hepatocellular carcinoma.

Reem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.

Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.

Rutika Mehta, MD, MPH, provides insight on the ongoing study combining TAS-102 with ramucirumab in the treatment of patients with advanced gastric/GEJ cancer.

Toni Choueiri, MD, discusses the biomarker analysis results from JAVELIN Renal 101 and provided insight on where the renal cell carcinoma field stands following pivotal data presented at the 2019 ASCO Annual Meeting.

Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

Thomas W. LeBlanc, MD, shares advice for community oncologists on to how to better navigate the complex treatment paradigm of acute myeloid leukemia.

Lindsay A.M. Rein, MD, discusses the current state of TKI discontinuation in patients with chronic myeloid leukemia.

Carlos Manuel de Castro III, MD, highlights current treatment approaches for severe aplastic anemia and some of the unmet needs that still exist.

Harry P. Erba, MD, PhD, provides insight into how to navigate through the targeted therapies available in the treatment of acute myeloid leukemia and discussed the work that lies ahead in this space.

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Cristina Gasparetto, MD, discusses the rapidly evolving field of relapsed/refractory myeloma.

Corey J. Langer, MD, highlights how precision medicine has emerged in the treatment of patients with non–small cell lung cancer via targeted therapies and checkpoint inhibitors.

Mark M. Zalupski, MD, sheds light on the current treatment landscape of advanced gastric cancer and the numerous challenges that remain.

Ana Oaknin, MD, provides insight into the implications of the GARNET trial and the promise of dostarlimab in endometrial cancer.

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.